AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2021-08, Vol.73 (3), p.531-534 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 534 |
|---|---|
| container_issue | 3 |
| container_start_page | 531 |
| container_title | Clinical infectious diseases |
| container_volume | 73 |
| creator | Ivashchenko, Andrey A Dmitriev, Kirill A Vostokova, Natalia V Azarova, Valeria N Blinow, Andrew A Egorova, Alina N Gordeev, Ivan G Ilin, Alexey P Karapetian, Ruben N Kravchenko, Dmitry V Lomakin, Nikita V Merkulova, Elena A Papazova, Natalia A Pavlikova, Elena P Savchuk, Nikolay P Simakina, Elena N Sitdekov, Tagir A Smolyarchuk, Elena A Tikhomolova, Elena G Yakubova, Elena V Ivachtchenko, Alexandre V |
| description | In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248. |
| doi_str_mv | 10.1093/cid/ciaa1176 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7454388</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2431806746</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-e84319a70dcdfbce186c1636f25a88d211a3676c4350b4a99f864719ecdaac9d3</originalsourceid><addsrcrecordid>eNpVkV9rFTEQxYMotlbffJY8VnBtsslmsz4IZWt1oaXlUutjmJvMeiO7m5rsFvS79Ls2l_6hfRhmyPw4c8Ih5D1nnzlrxIH1LhcA57V6QXZ5JepCVQ1_mWdW6UJqoXfIm5T-MMa5ZtVrsiPKumalZLvk5vCyO861on2I9CIizCNOMw09PYfZ5zHRX37e0NPgMMKMtA0xTHDt45LokU8ICWnJeEP327PL7qjgzccvtJtmjH6kK0zLkCWyHNDzzZbtuoOu6-hpfvcWtxxdweTC6P-jo-3gJ29hyFY8DG_Jqx6GhO_u-x75efztov1RnJx979rDk8IKLecCtRS8gZo56_q1Ra6V5UqovqxAa1dyDkLVykpRsbWEpum1kjVv0DoA2zixR77e6V4t6xHd1laEwVzlL0D8ZwJ483wz-Y35Ha5NLSsptM4C-_cCMfxdMM1m9MniMMCEYUmmzAY1U7VUGf10h9oYUorYP57hzGwTNTlR85Boxj88tfYIP0QobgFymJ2u</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2431806746</pqid></control><display><type>article</type><title>AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Ivashchenko, Andrey A ; Dmitriev, Kirill A ; Vostokova, Natalia V ; Azarova, Valeria N ; Blinow, Andrew A ; Egorova, Alina N ; Gordeev, Ivan G ; Ilin, Alexey P ; Karapetian, Ruben N ; Kravchenko, Dmitry V ; Lomakin, Nikita V ; Merkulova, Elena A ; Papazova, Natalia A ; Pavlikova, Elena P ; Savchuk, Nikolay P ; Simakina, Elena N ; Sitdekov, Tagir A ; Smolyarchuk, Elena A ; Tikhomolova, Elena G ; Yakubova, Elena V ; Ivachtchenko, Alexandre V</creator><creatorcontrib>Ivashchenko, Andrey A ; Dmitriev, Kirill A ; Vostokova, Natalia V ; Azarova, Valeria N ; Blinow, Andrew A ; Egorova, Alina N ; Gordeev, Ivan G ; Ilin, Alexey P ; Karapetian, Ruben N ; Kravchenko, Dmitry V ; Lomakin, Nikita V ; Merkulova, Elena A ; Papazova, Natalia A ; Pavlikova, Elena P ; Savchuk, Nikolay P ; Simakina, Elena N ; Sitdekov, Tagir A ; Smolyarchuk, Elena A ; Tikhomolova, Elena G ; Yakubova, Elena V ; Ivachtchenko, Alexandre V</creatorcontrib><description>In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciaa1176</identifier><identifier>PMID: 32770240</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Antiviral Agents - therapeutic use ; Brief Reports ; COVID-19 ; Drug Therapy, Combination ; Humans ; SARS-CoV-2 ; Treatment Outcome</subject><ispartof>Clinical infectious diseases, 2021-08, Vol.73 (3), p.531-534</ispartof><rights>The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.</rights><rights>The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-e84319a70dcdfbce186c1636f25a88d211a3676c4350b4a99f864719ecdaac9d3</citedby><cites>FETCH-LOGICAL-c384t-e84319a70dcdfbce186c1636f25a88d211a3676c4350b4a99f864719ecdaac9d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32770240$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ivashchenko, Andrey A</creatorcontrib><creatorcontrib>Dmitriev, Kirill A</creatorcontrib><creatorcontrib>Vostokova, Natalia V</creatorcontrib><creatorcontrib>Azarova, Valeria N</creatorcontrib><creatorcontrib>Blinow, Andrew A</creatorcontrib><creatorcontrib>Egorova, Alina N</creatorcontrib><creatorcontrib>Gordeev, Ivan G</creatorcontrib><creatorcontrib>Ilin, Alexey P</creatorcontrib><creatorcontrib>Karapetian, Ruben N</creatorcontrib><creatorcontrib>Kravchenko, Dmitry V</creatorcontrib><creatorcontrib>Lomakin, Nikita V</creatorcontrib><creatorcontrib>Merkulova, Elena A</creatorcontrib><creatorcontrib>Papazova, Natalia A</creatorcontrib><creatorcontrib>Pavlikova, Elena P</creatorcontrib><creatorcontrib>Savchuk, Nikolay P</creatorcontrib><creatorcontrib>Simakina, Elena N</creatorcontrib><creatorcontrib>Sitdekov, Tagir A</creatorcontrib><creatorcontrib>Smolyarchuk, Elena A</creatorcontrib><creatorcontrib>Tikhomolova, Elena G</creatorcontrib><creatorcontrib>Yakubova, Elena V</creatorcontrib><creatorcontrib>Ivachtchenko, Alexandre V</creatorcontrib><title>AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248.</description><subject>Antiviral Agents - therapeutic use</subject><subject>Brief Reports</subject><subject>COVID-19</subject><subject>Drug Therapy, Combination</subject><subject>Humans</subject><subject>SARS-CoV-2</subject><subject>Treatment Outcome</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkV9rFTEQxYMotlbffJY8VnBtsslmsz4IZWt1oaXlUutjmJvMeiO7m5rsFvS79Ls2l_6hfRhmyPw4c8Ih5D1nnzlrxIH1LhcA57V6QXZ5JepCVQ1_mWdW6UJqoXfIm5T-MMa5ZtVrsiPKumalZLvk5vCyO861on2I9CIizCNOMw09PYfZ5zHRX37e0NPgMMKMtA0xTHDt45LokU8ICWnJeEP327PL7qjgzccvtJtmjH6kK0zLkCWyHNDzzZbtuoOu6-hpfvcWtxxdweTC6P-jo-3gJ29hyFY8DG_Jqx6GhO_u-x75efztov1RnJx979rDk8IKLecCtRS8gZo56_q1Ra6V5UqovqxAa1dyDkLVykpRsbWEpum1kjVv0DoA2zixR77e6V4t6xHd1laEwVzlL0D8ZwJ483wz-Y35Ha5NLSsptM4C-_cCMfxdMM1m9MniMMCEYUmmzAY1U7VUGf10h9oYUorYP57hzGwTNTlR85Boxj88tfYIP0QobgFymJ2u</recordid><startdate>20210802</startdate><enddate>20210802</enddate><creator>Ivashchenko, Andrey A</creator><creator>Dmitriev, Kirill A</creator><creator>Vostokova, Natalia V</creator><creator>Azarova, Valeria N</creator><creator>Blinow, Andrew A</creator><creator>Egorova, Alina N</creator><creator>Gordeev, Ivan G</creator><creator>Ilin, Alexey P</creator><creator>Karapetian, Ruben N</creator><creator>Kravchenko, Dmitry V</creator><creator>Lomakin, Nikita V</creator><creator>Merkulova, Elena A</creator><creator>Papazova, Natalia A</creator><creator>Pavlikova, Elena P</creator><creator>Savchuk, Nikolay P</creator><creator>Simakina, Elena N</creator><creator>Sitdekov, Tagir A</creator><creator>Smolyarchuk, Elena A</creator><creator>Tikhomolova, Elena G</creator><creator>Yakubova, Elena V</creator><creator>Ivachtchenko, Alexandre V</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210802</creationdate><title>AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial</title><author>Ivashchenko, Andrey A ; Dmitriev, Kirill A ; Vostokova, Natalia V ; Azarova, Valeria N ; Blinow, Andrew A ; Egorova, Alina N ; Gordeev, Ivan G ; Ilin, Alexey P ; Karapetian, Ruben N ; Kravchenko, Dmitry V ; Lomakin, Nikita V ; Merkulova, Elena A ; Papazova, Natalia A ; Pavlikova, Elena P ; Savchuk, Nikolay P ; Simakina, Elena N ; Sitdekov, Tagir A ; Smolyarchuk, Elena A ; Tikhomolova, Elena G ; Yakubova, Elena V ; Ivachtchenko, Alexandre V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-e84319a70dcdfbce186c1636f25a88d211a3676c4350b4a99f864719ecdaac9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Brief Reports</topic><topic>COVID-19</topic><topic>Drug Therapy, Combination</topic><topic>Humans</topic><topic>SARS-CoV-2</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ivashchenko, Andrey A</creatorcontrib><creatorcontrib>Dmitriev, Kirill A</creatorcontrib><creatorcontrib>Vostokova, Natalia V</creatorcontrib><creatorcontrib>Azarova, Valeria N</creatorcontrib><creatorcontrib>Blinow, Andrew A</creatorcontrib><creatorcontrib>Egorova, Alina N</creatorcontrib><creatorcontrib>Gordeev, Ivan G</creatorcontrib><creatorcontrib>Ilin, Alexey P</creatorcontrib><creatorcontrib>Karapetian, Ruben N</creatorcontrib><creatorcontrib>Kravchenko, Dmitry V</creatorcontrib><creatorcontrib>Lomakin, Nikita V</creatorcontrib><creatorcontrib>Merkulova, Elena A</creatorcontrib><creatorcontrib>Papazova, Natalia A</creatorcontrib><creatorcontrib>Pavlikova, Elena P</creatorcontrib><creatorcontrib>Savchuk, Nikolay P</creatorcontrib><creatorcontrib>Simakina, Elena N</creatorcontrib><creatorcontrib>Sitdekov, Tagir A</creatorcontrib><creatorcontrib>Smolyarchuk, Elena A</creatorcontrib><creatorcontrib>Tikhomolova, Elena G</creatorcontrib><creatorcontrib>Yakubova, Elena V</creatorcontrib><creatorcontrib>Ivachtchenko, Alexandre V</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ivashchenko, Andrey A</au><au>Dmitriev, Kirill A</au><au>Vostokova, Natalia V</au><au>Azarova, Valeria N</au><au>Blinow, Andrew A</au><au>Egorova, Alina N</au><au>Gordeev, Ivan G</au><au>Ilin, Alexey P</au><au>Karapetian, Ruben N</au><au>Kravchenko, Dmitry V</au><au>Lomakin, Nikita V</au><au>Merkulova, Elena A</au><au>Papazova, Natalia A</au><au>Pavlikova, Elena P</au><au>Savchuk, Nikolay P</au><au>Simakina, Elena N</au><au>Sitdekov, Tagir A</au><au>Smolyarchuk, Elena A</au><au>Tikhomolova, Elena G</au><au>Yakubova, Elena V</au><au>Ivachtchenko, Alexandre V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2021-08-02</date><risdate>2021</risdate><volume>73</volume><issue>3</issue><spage>531</spage><epage>534</epage><pages>531-534</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>32770240</pmid><doi>10.1093/cid/ciaa1176</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2021-08, Vol.73 (3), p.531-534 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7454388 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Antiviral Agents - therapeutic use Brief Reports COVID-19 Drug Therapy, Combination Humans SARS-CoV-2 Treatment Outcome |
| title | AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T00%3A27%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AVIFAVIR%20for%20Treatment%20of%20Patients%20With%20Moderate%20Coronavirus%20Disease%202019%20(COVID-19):%20Interim%20Results%20of%20a%20Phase%20II/III%20Multicenter%20Randomized%20Clinical%20Trial&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Ivashchenko,%20Andrey%20A&rft.date=2021-08-02&rft.volume=73&rft.issue=3&rft.spage=531&rft.epage=534&rft.pages=531-534&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciaa1176&rft_dat=%3Cproquest_pubme%3E2431806746%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2431806746&rft_id=info:pmid/32770240&rfr_iscdi=true |